New to Meducation?
Sign up
Already signed up? Log In

Resources

Category

11
0
0

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
8
0
0

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
13
0
0

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
13
0
0

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
0
0
0

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
1
0
0

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
4
0
0

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
11
0
0

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
13
0
0

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
12
0
0

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
9
0
0

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
3
0
0

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
5
0
1

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
9
0
3

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
10
0
3

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
6
0
3

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
11
0
1

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
6
0
1

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
7
0
3

Loading...

 
ncbi.nlm.nih.gov
over 1 year ago
Preview
0
1

Levosimendan: 30 years of data and developments | Acute and Advanced Heart Failure | epgonline.org

Professor Pölzl discusses levosimendan and the REFALS 3 trial, which will evaluate the impact of levosimendan on respiratory function in patients with acute lateral sclerosis (ALS).  
epgonline.org
over 1 year ago